CN110003079A - 用于使心脏神经支配成像的配体 - Google Patents

用于使心脏神经支配成像的配体 Download PDF

Info

Publication number
CN110003079A
CN110003079A CN201910053427.0A CN201910053427A CN110003079A CN 110003079 A CN110003079 A CN 110003079A CN 201910053427 A CN201910053427 A CN 201910053427A CN 110003079 A CN110003079 A CN 110003079A
Authority
CN
China
Prior art keywords
nmr
alkyl
aryl
compound
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910053427.0A
Other languages
English (en)
Chinese (zh)
Inventor
A.普罗希特
T.D.哈里斯
H.S.拉德克
S.P.罗宾逊
M.于
D.S.凯斯比尔
M.T.阿泽雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantheus Medical Imaging Inc
Original Assignee
Lantheus Medical Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantheus Medical Imaging Inc filed Critical Lantheus Medical Imaging Inc
Publication of CN110003079A publication Critical patent/CN110003079A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/70—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/06—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201910053427.0A 2006-12-26 2007-12-21 用于使心脏神经支配成像的配体 Pending CN110003079A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87721106P 2006-12-26 2006-12-26
US60/877211 2006-12-26
CN200780051773.0A CN101687780B (zh) 2006-12-26 2007-12-21 用于使心脏神经支配成像的配体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200780051773.0A Division CN101687780B (zh) 2006-12-26 2007-12-21 用于使心脏神经支配成像的配体

Publications (1)

Publication Number Publication Date
CN110003079A true CN110003079A (zh) 2019-07-12

Family

ID=39307501

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910053427.0A Pending CN110003079A (zh) 2006-12-26 2007-12-21 用于使心脏神经支配成像的配体
CN201510856954.7A Expired - Fee Related CN105622463B (zh) 2006-12-26 2007-12-21 用于使心脏神经支配成像的配体
CN200780051773.0A Expired - Fee Related CN101687780B (zh) 2006-12-26 2007-12-21 用于使心脏神经支配成像的配体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201510856954.7A Expired - Fee Related CN105622463B (zh) 2006-12-26 2007-12-21 用于使心脏神经支配成像的配体
CN200780051773.0A Expired - Fee Related CN101687780B (zh) 2006-12-26 2007-12-21 用于使心脏神经支配成像的配体

Country Status (20)

Country Link
US (5) US8491868B2 (enExample)
EP (5) EP2474523B1 (enExample)
JP (3) JP5656408B2 (enExample)
KR (4) KR101718160B1 (enExample)
CN (3) CN110003079A (enExample)
AU (1) AU2007339954B2 (enExample)
BR (1) BRPI0722082A8 (enExample)
CA (2) CA2673853C (enExample)
CO (1) CO6231002A2 (enExample)
DK (3) DK2114873T3 (enExample)
ES (3) ES2805286T3 (enExample)
IL (3) IL199563A (enExample)
MX (2) MX367292B (enExample)
PL (1) PL2114873T3 (enExample)
PT (1) PT2114873E (enExample)
RU (1) RU2506256C2 (enExample)
SG (1) SG177918A1 (enExample)
TW (2) TWI618544B (enExample)
WO (1) WO2008083056A2 (enExample)
ZA (1) ZA200904828B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
ES2805286T3 (es) 2006-12-26 2021-02-11 Lantheus Medical Imaging Inc Ligandos para la formación de imágenes de la inervación cardíaca
AU2011213568B2 (en) 2010-02-08 2016-05-12 Lantheus Medical Imaging, Inc. Methods and apparatus for synthesizing imaging agents, and intermediates thereof
RU2710736C2 (ru) 2010-05-11 2020-01-10 Лантеус Медикал Имэджинг, Инк. Композиции, способы и системы для синтеза и применение визуализирующих средств
CA2799403C (en) * 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
US8981083B2 (en) 2010-05-14 2015-03-17 Dana Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
AR086113A1 (es) 2011-04-30 2013-11-20 Abbott Lab Isoxazolinas como agentes terapeuticos
CA3123737A1 (en) * 2011-09-09 2013-03-14 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
SG10201608370TA (en) 2012-04-10 2016-11-29 Lantheus Medical Imaging Inc Radiopharmaceutical synthesis methods
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
WO2014052454A1 (en) * 2012-09-25 2014-04-03 The Regents Of The University Of Michigan Imaging agents
US20150366523A1 (en) 2013-01-24 2015-12-24 Shlomo Ben-Haim Neuronal imaging and treatment
AU2014208379A1 (en) * 2013-01-24 2015-07-23 Tylerton International Holdings Inc. Body structure imaging
US20160027342A1 (en) * 2013-03-11 2016-01-28 Shlomo Ben-Haim Modeling the autonomous nervous system and uses thereof
EP3024327B1 (en) 2013-07-25 2019-09-04 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
US20160220835A1 (en) 2013-09-08 2016-08-04 Tylerton International Inc. Apparatus and methods for diagnosis and treatment of patterns of nervous system activity affecting disease
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
US10646183B2 (en) 2014-01-10 2020-05-12 Tylerton International Inc. Detection of scar and fibrous cardiac zones
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
RU2722179C2 (ru) 2014-02-28 2020-05-28 Тэнша Терапеутикс, Инк. Лечение состояний, ассоциированных с гиперинсулинемией
WO2016016839A1 (en) 2014-07-30 2016-02-04 Navix International Limited Registering nuclear medicine data
JP2017525759A (ja) 2014-08-08 2017-09-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジヒドロプテリジノン誘導体およびその使用
CA2955074A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996977A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
BR112018004618A2 (pt) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. ciano tienotriazoldiazepinas e usos das mesmas
US10913752B2 (en) 2015-11-25 2021-02-09 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
CN107892651A (zh) * 2017-11-29 2018-04-10 陕西慧康生物科技有限责任公司 一种合成dl‑盐酸麻黄碱的方法
SG11202103731QA (en) * 2018-10-15 2021-05-28 Bristol Myers Squibb Co Radioligands for imaging the lpa1 receptor
EP3682906A1 (en) * 2019-01-17 2020-07-22 Julius-Maximilians-Universität Würzburg Compound targeting norepinephrine transporter
CN109748825B (zh) * 2019-02-01 2022-02-18 原子高科股份有限公司 一种18f标记的胍甲基取代苯类似物及其应用
KR102690858B1 (ko) 2020-07-14 2024-08-02 한국과학기술원 이산화탄소와 개미산만으로 성장 가능한 재조합 미생물 및 상기 재조합 미생물을 이용하여 유용물질을 제조하는 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1118347A (zh) * 1993-08-03 1996-03-13 赫彻斯特股份公司 苯并五员杂环、其制法和作为药物和诊断药的用途
WO2005095345A2 (en) * 2004-03-23 2005-10-13 Achillion Pharmaceuticals, Inc. Heteroaryl guanidines as inhibitors of viral replication
US20060127309A1 (en) * 2004-12-10 2006-06-15 The Regents Of The University Of Michigan Imaging agents

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6012A (en) * 1849-01-09 Lithographing co
FR1010218A (fr) 1949-02-10 1952-06-09 American Cyanamid Co Perfectionnements aux sels de guanidine
GB1215255A (en) 1968-03-13 1970-12-09 Pfizer & Co C Halophenylalkylguanidine compounds
US4094881A (en) 1976-03-10 1978-06-13 Smithkline Corporation Process for preparing triazolethiols
US4275074A (en) 1979-03-09 1981-06-23 Graham J. Dobbie Catecholamine treatment of ocular hypertension
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4258188A (en) * 1980-02-04 1981-03-24 American Home Products Corporation 2-(1-Piperazinyl)-cycloheptimidazole derivatives
US4622217A (en) * 1984-04-27 1986-11-11 The Regents Of The University Of Michigan I-4-amino-3-iodobenzylguanidine as imaging and therapeutic agent
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
AU1503888A (en) * 1987-04-24 1988-10-27 King Faisal Specialist Hospital & Research Centre Method of producing iodine124 and meta-iodobenzlyguanidine containing iodine124
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5674865A (en) * 1991-10-18 1997-10-07 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
TW279864B (enExample) * 1993-02-19 1996-07-01 Janssen Pharmaceutica Nv
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
EP0841951A2 (en) 1995-06-26 1998-05-20 Concat Ltd. Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy and diagnosis
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
AU5362998A (en) 1996-11-27 1998-06-22 Du Pont Pharmaceuticals Company Novel integrin receptor antagonists
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
CA2345710C (en) 1997-10-02 2008-12-30 The University Of Western Ontario Preparation of radiolabelled haloaromatics via polymer-bound intermediates
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
AU3406599A (en) 1998-04-09 1999-11-01 Institut Fur Diagnostikforschung Gmbh An Der Freien Universitat Berlin Novel benzyl guanidine derivatives for therapy and (in-vivo) and (in-vitro) diagnosis
AU5671699A (en) 1998-08-14 2000-03-06 Smithkline Beecham Corporation Grp receptor ligands
JP2002532440A (ja) 1998-12-18 2002-10-02 デュポン ファーマシューティカルズ カンパニー ビトロネクチン受容体拮抗剤薬剤
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
DE10114561A1 (de) 2001-03-24 2002-09-26 Wella Ag Verwendung von Mitteln enthaltend Kreatin, Kreatin und/oder deren Derivaten zur Verstärkung und Strukturverbesserung von keratinischen Fasern
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
EP1581533A2 (en) 2002-08-17 2005-10-05 ALTANA Pharma AG Novel benzonaphthyridines
AU2003298582A1 (en) 2002-09-17 2004-05-13 Isis Pharmaceuticals, Inc. Therapeutic guanidines
CA2530087A1 (en) 2003-06-30 2005-02-03 Merck & Co., Inc. Radiolabeled cannabinoid-1 receptor modulators
WO2005053615A2 (en) * 2003-12-01 2005-06-16 Medi-Physics, Inc. Novel differential imaging method
JP4842123B2 (ja) * 2004-05-28 2011-12-21 浜松ホトニクス株式会社 放射性チロシン誘導体、その製造方法、放射性チロシン誘導体からなるポジトロンイメージング用標識剤及び腫瘍の悪性度評価薬剤並びに腫瘍の検出方法
WO2006032705A2 (en) 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging
US20060083681A1 (en) 2004-10-18 2006-04-20 Ajay Purohit Compounds for myocardial perfusion imaging
GB0512770D0 (en) 2005-06-23 2005-07-27 Hammersmith Imanet Ltd Imaging compounds
MX2009005920A (es) 2006-12-13 2009-06-16 Hoffmann La Roche Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina.
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
ES2805286T3 (es) * 2006-12-26 2021-02-11 Lantheus Medical Imaging Inc Ligandos para la formación de imágenes de la inervación cardíaca
WO2008082305A1 (en) 2006-12-28 2008-07-10 Raufoss Technology As Control arm
WO2008115593A1 (en) 2007-03-21 2008-09-25 The University Of Montana 1-[(2'-substituted)-piperazin-1'-yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents
CN103497201A (zh) 2007-10-18 2014-01-08 贝林格尔.英格海姆国际有限公司 二氢噻吩并[3,2-d]嘧啶的制备中使用的中间体及其制备
WO2010015340A1 (en) 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
GB0906274D0 (en) 2009-04-09 2009-05-20 Ge Healthcare Ltd Imaging the central nervous system
DK2419096T3 (da) 2009-04-15 2020-02-03 Lantheus Medical Imaging Inc Stabilisering af radiofarmaceutiske sammensætninger under anvendelse af ascorbinsyre
CN101555232B (zh) 2009-05-21 2011-01-05 北京师范大学 氟-18标记哒嗪酮类化合物及制备方法和应用
CA2803520C (en) 2009-07-08 2019-10-22 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
AU2011213568B2 (en) 2010-02-08 2016-05-12 Lantheus Medical Imaging, Inc. Methods and apparatus for synthesizing imaging agents, and intermediates thereof
RU2710736C2 (ru) 2010-05-11 2020-01-10 Лантеус Медикал Имэджинг, Инк. Композиции, способы и системы для синтеза и применение визуализирующих средств
CA3123737A1 (en) 2011-09-09 2013-03-14 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP2671575A1 (en) 2012-06-04 2013-12-11 Universität Regensburg Ras inhibitors
JP2017131851A (ja) 2016-01-29 2017-08-03 日本特殊陶業株式会社 マイクロ波加熱用触媒材料、マイクロ波加熱用触媒体、及び、その製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1118347A (zh) * 1993-08-03 1996-03-13 赫彻斯特股份公司 苯并五员杂环、其制法和作为药物和诊断药的用途
WO2005095345A2 (en) * 2004-03-23 2005-10-13 Achillion Pharmaceuticals, Inc. Heteroaryl guanidines as inhibitors of viral replication
US20060127309A1 (en) * 2004-12-10 2006-06-15 The Regents Of The University Of Michigan Imaging agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARITA HOGBERG等: "Bioisosteric Modi®cation of PETT-HIV-1 RT-Inhibitors: Synthesis and Biological Evaluation", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
R. N. HANSON: "Radioiodinated 1-Carboxamidino-4-Phenylpiperazine: A Potential Adrenal and Myocardial Imaging Radiopharmaceutical", 《INT. J. APPL. RADIAT. ISOT.》 *
STEFAN DAHMEN等: "A Novel Solid-Phase Synthesis of Highly Diverse Guanidines: Reactions of Primary Amines Attached to the T2* Linker", 《ORGANIC LETTERS》 *

Also Published As

Publication number Publication date
CA2984226C (en) 2021-02-23
US20180339070A1 (en) 2018-11-29
WO2008083056A2 (en) 2008-07-10
CN101687780B (zh) 2016-01-20
CN101687780A (zh) 2010-03-31
JP6021860B2 (ja) 2016-11-09
US20220288243A1 (en) 2022-09-15
EP2474526A2 (en) 2012-07-11
CA2673853A1 (en) 2008-07-10
ZA200904828B (en) 2014-12-23
EP2474523B1 (en) 2020-04-08
BRPI0722082A2 (pt) 2014-04-01
KR20090097946A (ko) 2009-09-16
US20250161500A1 (en) 2025-05-22
CA2673853C (en) 2017-10-31
RU2009128591A (ru) 2011-02-10
KR101718160B1 (ko) 2017-03-20
KR20170102580A (ko) 2017-09-11
PL2114873T3 (pl) 2013-08-30
TWI618544B (zh) 2018-03-21
JP2014237679A (ja) 2014-12-18
DK2474525T3 (da) 2020-07-13
AU2007339954A1 (en) 2008-07-10
ES2804801T3 (es) 2021-02-09
AU2007339954B2 (en) 2013-06-20
PT2114873E (pt) 2013-05-06
MX367292B (es) 2019-08-13
DK2114873T3 (da) 2013-05-13
KR20140140134A (ko) 2014-12-08
US12324845B2 (en) 2025-06-10
ES2805286T3 (es) 2021-02-11
US11241509B2 (en) 2022-02-08
IL224396B (en) 2018-04-30
EP2474523A2 (en) 2012-07-11
JP2010514786A (ja) 2010-05-06
JP2016183164A (ja) 2016-10-20
IL253885A0 (en) 2017-10-31
CO6231002A2 (es) 2010-12-20
EP2474526A3 (en) 2012-07-25
TW201628660A (zh) 2016-08-16
SG177918A1 (en) 2012-02-28
EP2474524A3 (en) 2012-07-18
ES2405655T3 (es) 2013-05-31
US8491868B2 (en) 2013-07-23
EP2114873A2 (en) 2009-11-11
EP2474524A2 (en) 2012-07-11
JP5656408B2 (ja) 2015-01-21
EP2474525B1 (en) 2020-04-15
US20140030189A1 (en) 2014-01-30
RU2506256C2 (ru) 2014-02-10
CN105622463B (zh) 2019-02-22
CN105622463A (zh) 2016-06-01
EP2474525A2 (en) 2012-07-11
EP2114873B1 (en) 2013-02-20
TW200848078A (en) 2008-12-16
HK1138260A1 (en) 2010-08-20
MX2009007018A (es) 2009-11-26
CA2984226A1 (en) 2008-07-10
TWI549692B (zh) 2016-09-21
DK2474523T3 (da) 2020-07-13
US10010631B2 (en) 2018-07-03
BRPI0722082A8 (pt) 2018-03-13
KR20160049044A (ko) 2016-05-04
EP2474525A3 (en) 2012-07-25
WO2008083056A3 (en) 2009-04-30
US20100221182A1 (en) 2010-09-02
KR101810348B1 (ko) 2017-12-18
EP2474523A3 (en) 2012-07-18
IL199563A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
CN105622463B (zh) 用于使心脏神经支配成像的配体
US20090004106A1 (en) Radioligands for the 5 -Ht1b Receptor
US20110009419A1 (en) Enantiomers of 2'-Fluoralkyl-6-nitroquipazine as Serotonin Transporter Positron Emission Tomography Imaging Agents and Antidepressant Therapeutics
TW202444713A (zh) 靶向成纖維細胞活化蛋白的配體
US20140140928A1 (en) 5ht1a antagonist useful for in vivo imaging
HK40011061A (en) Ligands for imaging cardiac innervation
CN107406419A (zh) Pet显像剂
HK1173429A (en) Ligands for imaging cardiac innervation
HK1173429B (en) Ligands for imaging cardiac innervation
HK1138260B (en) N-[3-bromo-4-(3- [18f]fluoropropoxy)-benzyl]-guanidine for imaging cardiac innervation
HK1173430B (en) Ligands for imaging cardiac innervation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011061

Country of ref document: HK